Literature DB >> 21315399

Physical therapy assessment tools to evaluate disease progression and phenotype variability in Golden Retriever muscular dystrophy.

T P Gaiad1, M B Silva, G C A Silva, F A Caromano, M A Miglino, C E Ambrósio.   

Abstract

Dogs suffering from Golden Retriever muscular dystrophy (GRMD) present symptoms that are similar to human patients with Duchenne muscular dystrophy (DMD). Phenotypic variability is common in both cases and correlates with disease progression and response to therapy. Physical therapy assessment tools were used to study disease progression and assess phenotypic variability in dogs with GRMD. At 5 (T0), 9 (T1), 13 (T2) and 17 (T3)months of age, the physical features, joint ranges of motion (ROM), limb and thorax circumferences, weight and creatine kinase (CK) levels were assessed in 11 dogs with GRMD. Alterations of physical features were higher at 13 months, and different disease progression rates were observed. Passive ROM decreased until 1 year old, which was followed by a decline of elbow and tarsal ROM. Limb and thorax circumferences, which were corrected for body weight, decreased significantly between T0 and T3. These measurements can be used to evaluate disease progression in dogs with GRMD and to help discover new therapies for DMD patients.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21315399     DOI: 10.1016/j.rvsc.2011.01.007

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  6 in total

1.  Quantitative phenotyping of Duchenne muscular dystrophy dogs by comprehensive gait analysis and overnight activity monitoring.

Authors:  Jin-Hong Shin; Brian Greer; Chady H Hakim; Zhongna Zhou; Yu-chia Chung; Ye Duan; Zhihai He; Dongsheng Duan
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

2.  Profiles of Steroid Hormones in Canine X-Linked Muscular Dystrophy via Stable Isotope Dilution LC-MS/MS.

Authors:  Helio A Martins-Júnior; Rosineide C Simas; Marina P Brolio; Christina R Ferreira; Felipe Perecin; Guilherme de P Nogueira; Maria A Miglino; Daniele S Martins; Marcos N Eberlin; Carlos E Ambrósio
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

3.  Motor physical therapy affects muscle collagen type I and decreases gait speed in dystrophin-deficient dogs.

Authors:  Thaís P Gaiad; Karla P C Araujo; Júlio C Serrão; Maria A Miglino; Carlos Eduardo Ambrósio
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

4.  Night Activity Reduction is a Signature Physiological Biomarker for Duchenne Muscular Dystrophy Dogs.

Authors:  Chady H Hakim; Austin A Peters; Feng Feng; Gang Yao; Dongsheng Duan
Journal:  J Neuromuscul Dis       Date:  2015

Review 5.  Appendicular skeletal muscle mass assessment in dogs: a scoping literature review.

Authors:  Ah Young Kim; Lindsay Hochman Elam; Nicolaas Everhardus Lambrechts; Mo D Salman; Felix Michael Duerr
Journal:  BMC Vet Res       Date:  2022-07-16       Impact factor: 2.792

6.  Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.

Authors:  Karla P C Araujo; Gloria Bonuccelli; Caio N Duarte; Thais P Gaiad; Dayson F Moreira; David Feder; José E Belizario; Maria A Miglino; Michael P Lisanti; Carlos E Ambrosio
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.